Carotid Stenting: CREST Makes A Splash, But Market Will Depend On CMS
This article was originally published in The Gray Sheet
Executive Summary
Carotid stent makers and interventionalists plan to use recently reported CREST trial data to argue for expanded Medicare coverage that allows more patients to receive the devices, but potential obstacles remain
You may also be interested in...
CMS Restricts Coverage For Devices More Than Drugs, Study Finds
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.
CMS Restricts Coverage For Devices More Than Drugs, Study Finds
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.
Live Transmission Of TAVR Found Safe, And More From Annual SCAI Conference
Interventional cardiologists presented new data at the annual meeting of The Society for Cardiovascular Angiography and Interventions supporting the safe use of live video transmission of transcatheter aortic valve replacement cases, and results from other late-breaking clinical trials.